Curanex Reports Q1 2026 Progress; Phyto-N IND Targeted for Q4 2026
Curanex Pharmaceuticals reported progress on its lead drug candidate, Phyto-N, in a first quarter 2026 business update furnished under Regulation FD. The company completed a GMP pilot-scale batch and a dose-range finding toxicology study, and added cancer cachexia as a new pipeline indication. The filing reports no revenue or earnings figures, and shareholders would note that cash and cash equivalents were approximately $4.0 million as of March 31, 2026.
Key points
- Planned IND submission to the FDA for ulcerative colitis targeted for the fourth quarter of 2026
- GMP-compliant pilot-scale batch of Phyto-N completed in February 2026; 28-day toxicology study in rats and dogs completed in March 2026
- Cancer cachexia added as a new core indication after quarter-end; cited market estimate of approximately $2.54 billion in 2024
- Cash and cash equivalents of approximately $4.0 million as of March 31, 2026
The filing
Written by AI on Nov 9, 2026, 11:46 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on May 14, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.